<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638426</url>
  </required_header>
  <id_info>
    <org_study_id>HL237-201</org_study_id>
    <nct_id>NCT04638426</nct_id>
  </id_info>
  <brief_title>Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis</brief_title>
  <official_title>For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in&#xD;
      rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups&#xD;
      of HL237 tablets and the control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20(american college of rheumatology 20) response rate</measure>
    <time_frame>at 12 weeks after administering investigational products</time_frame>
    <description>ACR20(american college of rheumatology 20) response rate at 12 weeks after administering investigational products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20(american college of rheumatology 20) response rate</measure>
    <time_frame>at 4, 8 weeks after administering investigational products</time_frame>
    <description>ACR20(american college of rheumatology 20) response rate at 4, 8 weeks after administering investigational products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-ESR(Disease Activity Score 28- erythrocyte sedimentation rate) score</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of DAS28-ESR(Disease Activity Score 28- erythrocyte sedimentation rate) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP(Disease Activity Score 28-C-reactive protein) score</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of DAS28-CRP(Disease Activity Score 28-C-reactive protein) score Change of DAS28-ESR(Disease Activity Score 28- erythrocyte sedimentation rate) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender joint count</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Tender joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen joint count</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Swollen joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's composite assessment of disease activity</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Investigator's composite assessment of disease activity (100 mm visual analog scale (0: not active at all, 100: most severely active))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's composite assessment of disease activity</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Subject's composite assessment of disease activity (100 mm visual analog scale (0: not active at all, 100: most severely active))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of pain (visual analog scale)</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Subject's assessment of pain (100 mm visual analog scale(0: no pain, 100: severe pain))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of physical function (Korean health assessment questionnaire)</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Subject's assessment of physical function (Korean health assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of Erythrocyte Sedimentation Rate (ESR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of C-Reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morning stiffness duration</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of morning stiffness duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average number of times of use the remedy per day</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of The average number of times of use the remedy per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who use the remedy</measure>
    <time_frame>at 4, 8, 12 weeks after administering investigational products</time_frame>
    <description>Change of the percentage of subjects who use the remedy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 tab. 200mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 tab. 400mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 tab. 800mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of HL237 tab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL237 tablet</intervention_name>
    <description>Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of HL237 tablet</intervention_name>
    <description>Placebo of HL237, twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, 19 years ≤ age ≤ 80 years&#xD;
&#xD;
          -  In the case of women of childbearing age, those who have a negative pregnancy test&#xD;
             before randomization&#xD;
&#xD;
          -  Patients who agree to use a medically accepted method of contraception during the&#xD;
             clinical trial&#xD;
&#xD;
          -  Patients corresponding to ACR functional class Ⅰ,Ⅱ,Ⅲ&#xD;
&#xD;
          -  Patients with active rheumatoid arthritis with DAS28-ESR &gt; 3.2 in the evaluation of&#xD;
             DAS28-ESR identified at the screening&#xD;
&#xD;
          -  Patients who were diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR&#xD;
             classification criteria at least 3 months prior to the screening, and showed&#xD;
             insufficient response or refractory to treatment with one or more DMARDs.&#xD;
&#xD;
          -  Among the subjects who have previously been continuously administering the following&#xD;
             rheumatoid arthritis drugs without stopping, those who have used them according to the&#xD;
             conditions before randomization and can maintain the current administration regimen&#xD;
             and dose during the clinical trial.&#xD;
&#xD;
               -  cDMARDs : Patients who received the same cDMARDs for 12 weeks or more&#xD;
                  continuously and did not change the dosage and administration of the cDMARDs for&#xD;
                  4 weeks or more until the 2nd visit(ex. methotrexate, sulfasalazine,&#xD;
                  hydroxychloroquine, leflunomide, bucillamine etc.)&#xD;
&#xD;
               -  Prednisolone : Patients who received corticosteroids with a daily dose of 10mg or&#xD;
                  less of oral prednisolone equivalent continuously, and did not change the dosage&#xD;
                  and administration for more than 2 weeks until the 2nd visit.&#xD;
&#xD;
               -  Tramadol or NSAIDs : Patients who did not change the dosage and administration&#xD;
                  for more than 2 weeks consecutively until the 2nd visit&#xD;
&#xD;
          -  Patients who have completed the wash-out period as follows until the 2nd visit&#xD;
             including the screening period (each period refers to the case where it continues&#xD;
             consecutively, and these drugs are contraindicated from the screening).&#xD;
&#xD;
               -  bDMARDs abatacept, adalimumab, certolizumab pegol, golimumab : 10 weeks or more&#xD;
                  anakinra : 10 days or more etanercept : 3 weeks or more infliximab : 8 weeks or&#xD;
                  more tocilizumab : 5 weeks or more rituximab : 6 months or more&#xD;
&#xD;
               -  JAK inhibitors tofacitinib, baricitinib : 2 weeks or more&#xD;
&#xD;
               -  immunosuppressants tacrolimus, cyclosporin, azathioprine, cyclophosphamide&#xD;
                  mizoribine etc : 4 weeks or more&#xD;
&#xD;
               -  tramadol, analgesics and anti-inflammatory analgesic other than NSAIDs : 4 days&#xD;
                  or more&#xD;
&#xD;
          -  Volunteer, be willing and able to provide written informed consent for the trial&#xD;
&#xD;
          -  Patients who can read and understand written instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients corresponding to ACR functional class Ⅳ&#xD;
&#xD;
          -  Patients with acquired immune deficiency syndrome or autoimmune diseases other than&#xD;
             rheumatoid arthritis&#xD;
&#xD;
          -  Severe heart failure, congestive heart failure (NYHA II～IV), ischemic heart disease,&#xD;
             peripheral artery disease and/or cerebrovascular disease&#xD;
&#xD;
          -  Patients with a history of gastrointestinal bleeding or perforation due to treatment&#xD;
             of nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Patients with bleeding or a current history of blood coagulation disorder&#xD;
&#xD;
          -  Patients suffering from infectious disease (including tuberculosis, shingles, etc.) at&#xD;
             the time of screening or undergoing treatment with the medical history&#xD;
&#xD;
          -  Patients with a history of malignant tumors within 5 years prior to screening&#xD;
&#xD;
          -  Patients with peptic ulcer confirmed by endoscopy or radiographic examination within 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  Patients with a history of gastric or duodenal perforation or obstruction, patients&#xD;
             with a history of gastrointestinal surgery (except appendicitis), and patients with a&#xD;
             history of upper or lower gastrointestinal bleeding (excluding simple hemorrhoids)&#xD;
             within the past year&#xD;
&#xD;
          -  Patients with symptoms or signs of pyloric obstruction&#xD;
&#xD;
          -  Patients diagnosed with malabsorption within 12 weeks prior to the screening&#xD;
&#xD;
          -  Patients with hypersensitive reaction or history of clinically significant&#xD;
             hypersensitive reaction to investigational product or its excipients&#xD;
&#xD;
          -  Patients with aspirin asthma (asthma attacks caused by nonsteroidal anti-inflammatory&#xD;
             drugs) or a history of the same&#xD;
&#xD;
          -  Patients with inflammatory bowel disease such as crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Patients administered intraarticular, intramuscular, intravenous corticosteroids&#xD;
             within 4 weeks priro to the screening.&#xD;
&#xD;
          -  Patients with significant psychiatric disorders or taking antidepressants,&#xD;
             anticonvulsants, or sedatives&#xD;
&#xD;
          -  Patients with substance or alcohol abuse or dependence&#xD;
&#xD;
          -  Patients who participate in other clinical trials within 12 weeks prior to the&#xD;
             screening and administer investigational drugs or apply clinical trial medical devices&#xD;
&#xD;
          -  Patients expected to inevitably administer contraindicated drugs during the clinical&#xD;
             trial&#xD;
&#xD;
          -  Patients with severe renal dysfuntion(seurum creatinine is 2.0 times higher than the&#xD;
             upper limit of normal (based on the institution))&#xD;
&#xD;
          -  Patients with severe liver dysfuntion(ALT, AST or total bilirubin is 2.0 times higher&#xD;
             than the upper limit of normal (based on the institution))&#xD;
&#xD;
          -  Patients that the investigator deems unsuitable for participation in the clinical&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul ST.MARY'S Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

